A one-year, phase I/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung disease - Wikidata - wikimedia - TriplyDB

A one-year, phase I/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung disease

A one-year, phase I/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung disease

http://www.wikidata.org/entity/Q35489187

about

Current perspectives on the immunopathogenesis of systemic sclerosis Recent Treatments of Interstitial Lung Disease with Systemic Sclerosis Treatment of rheumatoid arthritis-associated interstitial lung disease: a perspective review Cellular targeting in autoimmunity Pharmacology and rationale for imatinib in the treatment of scleroderma The role of biologics in treatment of connective tissue disease-associated interstitial lung disease An Update on the Treatment of the Cutaneous Manifestations of Systemic Sclerosis: The Dermatologist's Point of View.Dissecting the heterogeneity of skin gene expression patterns in systemic sclerosis Targeting the myofibroblast genetic switch: inhibitors of myocardin-related transcription factor/serum response factor-regulated gene transcription prevent fibrosis in a murine model of skin injury.Cellular mechanisms of tissue fibrosis. 8. Current and future drug targets in fibrosis: focus on Rho GTPase-regulated gene transcription.Treatment of connective tissue disease-associated interstitial lung disease: the pulmonologist's point of view.Systemic Sclerosis-Associated Interstitial Lung Disease: Lessons from Clinical Trials, Outcome Measures, and Future Study Design.Low-dose oral imatinib in the treatment of systemic sclerosis interstitial lung disease unresponsive to cyclophosphamide: a phase II pilot study.Safety profile of protein kinase inhibitors in rheumatoid arthritis: systematic review and meta-analysis.Review: interstitial lung disease associated with systemic sclerosis and idiopathic pulmonary fibrosis: how similar and distinct?Treatment with imatinib results in reduced IL-4-producing T cells, but increased CD4(+) T cells in the broncho-alveolar lavage of patients with systemic sclerosis.Nilotinib (Tasigna™) in the treatment of early diffuse systemic sclerosis: an open-label, pilot clinical trial Old medications and new targeted therapies in systemic sclerosis.A review of current and novel therapies for idiopathic pulmonary fibrosis Guidelines of the Brazilian society of bone Marrow transplantation on hematopoietic stem cell transplantation as a treatment for the autoimmune diseases systemic sclerosis and multiple sclerosis.Profibrotic TGFβ responses require the cooperative action of PDGF and ErbB receptor tyrosine kinases.Treatment of Rapidly Progressive Systemic Sclerosis: Current and Futures Perspectives Treatment of diffuse systemic sclerosis with hyperimmune caprine serum (AIMSPRO): a phase II double-blind placebo-controlled trial.Skin gene expression correlates of severity of interstitial lung disease in systemic sclerosis.Treatment of interstitial lung diseases associated with connective tissue diseases.Low-dose imatinib in the treatment of severe systemic sclerosis: a case series of six Chinese patients and literature review.Systemic sclerosis--challenges for clinical practice.The evolving pharmacotherapy of pulmonary fibrosis.Involvement of PDGF in fibrosis and scleroderma: recent insights from animal models and potential therapeutic opportunities PDGF and the progression of renal disease.Platelet-derived growth factor signaling in the lung. From lung development and disease to clinical studies.Systemic sclerosis: a systematic review on therapeutic management from 2011 to 2014.Update on systemic sclerosis.Strategy for treatment of fibrosis in systemic sclerosis: Present and future.Tyrosine Kinase Inhibitors in the Treatment of Systemic Sclerosis: The Difficulty in Interpreting Proof-of-Concept Studies.Interstitial lung disease in systemic sclerosis: current and future treatment.Treatment of Systemic Sclerosis-related Interstitial Lung Disease: A Review of Existing and Emerging Therapies.Imatinib mesylate-induced cutaneous rash masquerading as pityriasis rosea of gilbert.Proteomic Analysis of Sera from Individuals with Diffuse Cutaneous Systemic Sclerosis Reveals a Multianalyte Signature Associated with Clinical Improvement during Imatinib Mesylate Treatment.Bosentan reverses the pro-fibrotic phenotype of systemic sclerosis dermal fibroblasts via increasing DNA binding ability of transcription factor Fli1.

P2860

Q26741264-80E4EDEF-C740-4EC7-BE21-3B675701505F Q26773161-41122F3F-84BD-4AB8-8720-334C6EA9E6EA Q26775753-B08C7946-2488-4882-BB7E-A9BF70CC80AA Q26824580-73D8DD06-38BF-4061-9F31-83573F344279 Q26825153-3DE38258-1754-4017-B210-24FF69D9A480 Q28082021-95E9FB52-CEF7-4371-BED9-004CFA5EA23E Q30465733-E8FAD284-7575-4D1A-80A4-BE2EFF0D9BB2 Q30845649-52CEE323-DD78-403F-AC27-7147C5F97686 Q33603627-C9CD71CD-1312-4895-AFDF-96B118D39045 Q33840143-212FD65A-17A5-437A-B3F0-30CE807DD6A5 Q33907242-FA095BBC-2E49-47AA-B367-7C5C62B8FA50 Q34027197-C0498B16-B55E-423A-B55F-90AAEC56E23A Q34486262-ABD10612-6D15-4EBF-B000-4ABB87048420 Q34677487-9D1F2A73-768D-4240-8C98-90C3B4348CD9 Q35121494-C78CCE71-4713-4781-AD72-4CA876068951 Q35566387-530D9435-B266-43BB-901A-A5D1EAC7DAE6 Q35961706-6C1EB60C-C814-40C6-89E0-59EAEF5F4135 Q36154430-7675AA70-78FE-4207-BA14-45AC953184B4 Q36542274-4C71766F-BD42-493F-9498-9CA47C24E793 Q36901406-7A04B0A0-ED3C-4140-8609-A5044FD19C77 Q37245959-4C210A57-A09A-4462-87D2-43F120DD5C5A Q37381549-EC0AEB65-68B0-4E27-A8A7-87E274BD1E93 Q37465397-D414E8D5-3B6D-4E2A-B894-17B17563564F Q37503878-02F8704A-E6D5-4477-80F7-104C68879345 Q37990559-A503A796-F773-4B77-AE30-2B195787D138 Q38033125-1B8C75D8-5FED-4ECB-B871-96E46FA2510F Q38059459-2D37CE79-3489-4D08-8F74-B4A1E5BE998F Q38069617-23932D74-238E-48D6-A431-08F2323E6652 Q38073213-2F641AC0-D8C5-44D3-956F-70094E2982EA Q38185014-86FFB20F-E2EF-4039-91CA-3E9AE337E3DE Q38258904-C47F65A9-2559-4ED4-B9A9-AB7F2553CC30 Q38379767-EF665ED8-5ED9-4244-9467-66CA2026DC40 Q38542317-522F9A4A-2BC9-427C-8E0C-7606D0D27CAB Q38701990-88035762-7D17-4AF7-A886-B9CB568AC0EE Q38733768-CC2FADAE-F459-475A-BB5C-1362E7C4A398 Q38773637-E289FF6E-027C-44FA-AE09-AFDC49BD017F Q38936954-E484C4CF-E4BF-4844-881D-D624EB1C573D Q40041110-CD4F1236-D859-48FE-AD4B-A5EC9C6AA9DD Q40292542-7C3A2CDE-3162-4BF3-85D0-B249BBDF7145 Q40785888-C0846CCD-E27D-4348-AB03-39C023580593

P2860

A one-year, phase I/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung disease

http://www.wikidata.org/entity/Q35489187

description

2011 nî lūn-bûn

@nan

2011 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

A one-year, phase I/IIa, open- ...... tive interstitial lung disease

@ast

A one-year, phase I/IIa, open- ...... tive interstitial lung disease

@en

type

label

A one-year, phase I/IIa, open- ...... tive interstitial lung disease

@ast

A one-year, phase I/IIa, open- ...... tive interstitial lung disease

@en

prefLabel

A one-year, phase I/IIa, open- ...... tive interstitial lung disease

@ast

A one-year, phase I/IIa, open- ...... tive interstitial lung disease

@en

P1433

Q35489187-C72AA186-08D0-43A9-9933-D89C07FD65D8

P1476

Q35489187-A5165CFE-A326-4F84-AE5F-842F9FC82F18

P2093

Q35489187-2F8C65C5-800F-4D70-9A58-B1D368A1FF04

Q35489187-3E40E241-A65A-4739-A682-F0FCF78EF73B

Q35489187-50767825-7E51-4A1C-B317-3FC4ECDA47B4

Q35489187-754BDCAE-DEEF-465F-9FC4-5604DC3B7888

Q35489187-78543C53-0E42-4C1D-A933-9E256A8EDC7F

Q35489187-8CF7AFF9-9294-4ED7-8B47-1E05BB9399C9

Q35489187-9B0C0CDE-ADD2-485D-9507-DE9D8BCE84BA

Q35489187-C0451A30-0695-4F4A-94CE-CFDBCECED856

Q35489187-D61BA2F3-E208-4350-8057-C6ECB1BF6245

Q35489187-EFC3BF7D-D175-4435-9DB0-DB143FCB881D

P2860

Q35489187-1074240D-0FB1-41CA-8E97-A6A96E4FA16C

Q35489187-1F3F0CE7-0D03-42EB-B3F0-CD9B75ABE063

Q35489187-342515E3-7E40-4F82-9627-017775286134

Q35489187-439DC3D1-CF07-4DDC-83FD-BC319AE21E02

Q35489187-45146899-C294-4EC1-A25E-995047457F0F

Q35489187-47D7C8E9-51A8-42E4-91A4-98C8933F8FFA

Q35489187-503FB546-EA2E-40E8-9FE9-6C1E3B8BF1C3

Q35489187-5319CF41-3BCB-4EBC-B636-E33D95D5B8D2

Q35489187-62FBA5CE-DE16-4B88-92B9-49D2FA7ECD59

Q35489187-62FDF918-1F36-44F7-B479-173EC8979BC0

P304

Q35489187-682E5EB7-9CBD-4F4A-8474-78A673C8208E

P31

Q35489187-C0FBFD27-5D53-4C74-9C04-42727F4787D4

P356

Q35489187-05D418E9-02FA-42E7-9876-D02A6DE6732D

P433

Q35489187-A7A39A8E-8D4F-4F52-A8F3-7E47A592EA98

P478

Q35489187-6C426B01-167A-439B-8E7D-E84FFF0D0D12

P577

Q35489187-0BC448A5-3395-4D80-860C-7CE08A9702DA

P5875

Q35489187-82A4FE2B-CD24-485A-89CB-54003ECF6ED2

P698

Q35489187-56BBAB50-F8BD-44BC-87CD-68B246E606C2

P921

Q35489187-EDBEEE44-E607-4E57-AFA0-D4E1FD4A6CEB

P932

Q35489187-56F9F3E9-FFCE-4804-95DE-0CD4345ECC7E

P356

P1433

Arthritis & Rheumatology

P1476

A one-year, phase I/IIa, open- ...... tive interstitial lung disease

@en

P2093

Daniel E Furst

http://www.w3.org/2001/XMLSchema#string

Dinesh Khanna

http://www.w3.org/2001/XMLSchema#string

Fereidoun Abtin

http://www.w3.org/2001/XMLSchema#string

Maureen D Mayes

http://www.w3.org/2001/XMLSchema#string

Paul Maranian

http://www.w3.org/2001/XMLSchema#string

Philip J Clements

http://www.w3.org/2001/XMLSchema#string

Rajan Saggar

http://www.w3.org/2001/XMLSchema#string

Rajeev Saggar

http://www.w3.org/2001/XMLSchema#string

Ram R Singh

http://www.w3.org/2001/XMLSchema#string

Shervin Assassi

http://www.w3.org/2001/XMLSchema#string

P2860

Late treatment with imatinib mesylate ameliorates radiation-induced lung fibrosis in a mouse model

Cyclophosphamide versus placebo in scleroderma lung disease.

Minimally important difference in diffuse systemic sclerosis: results from the D-penicillamine study

Inhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosis.

Fibrosis in connective tissue disease: the role of the myofibroblast and fibroblast-epithelial cell interactions

Role of PDGF in fibrotic diseases and systemic sclerosis.

Course of the modified Rodnan skin thickness score in systemic sclerosis clinical trials: analysis of three large multicenter, double-blind, randomized controlled trials.

Minimally important differences in the Mahler's Transition Dyspnoea Index in a large randomized controlled trial--results from the Scleroderma Lung Study.

Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis.

Practical management of tyrosine kinase inhibitor-associated side effects in GIST.

P304

3540-3546

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/ART.30548

http://www.w3.org/2001/XMLSchema#string

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

63

http://www.w3.org/2001/XMLSchema#string

P577

2011-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51502866

http://www.w3.org/2001/XMLSchema#string

P698

21769849

http://www.w3.org/2001/XMLSchema#string

P921

phase I clinical trial

P932

3205223

http://www.w3.org/2001/XMLSchema#string